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Background. Clonorchiasis is of considerable public health importance, particularly in the People’s Republic
of China (PR China), where most of the 15 million individuals infected with Clonorchis sinensis are currently
concentrated. Praziquantel is the drug of choice, but tribendimidine might be an alternative.
Methods. We performed a randomized open-label trial in Guangxi, PR China, to assess the efﬁcacy and safety
of 400 mg tribendimidine once, 400 mg tribendimidine daily for 3 days, and 75 mg/kg praziquantel in 1 day
divided in 3 doses against parasitological-conﬁrmed C. sinensis infections. Cure and egg reduction rates were
determined 3 weeks posttreatment using available case analysis. Clinical symptoms were documented at baseline,
and adverse events were recorded and graded 3 and 24 hours after each dose.
Results. A total of 74 patients were included in the ﬁnal analysis. Single-dose tribendimidine achieved a cure
rate of 44%, whereas cure rates of 58% and 56% were obtained for tribendimidine administered for 3 days and
praziquantel, respectively. High egg reduction rates (97.6%–98.8%) were observed for all treatment regimens.
Single-dose tribendimidine was the best-tolerated treatment scheme. Patients treated with praziquantel experi-
enced signiﬁcantly more adverse events than did tribendimidine recipients (P < .05).
Conclusions. Tribendimidine has an efﬁcacy comparable to praziquantel in the treatment of C. sinensis infec-
tion and resulted in fewer adverse events compared to praziquantel. Larger clinical trials are warranted among
C. sinensis–infected patients to determine the potential of tribendimidine against clonorchiasis and other helmin-
thiases.
Clinical Trials Registration. Controlled-Trials.com, ISRCTN80829842.
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INTRODUCTION
An estimated 15 million people, most of them living
in the People’s Republic of China (PR China), are
infected with the liver ﬂuke Clonorchis sinensis, result-
ing in a global burden of at least 275 370 disability-
adjusted life-years (DALYs) [1]. The consumption of
raw freshwater ﬁsh is a popular tradition not just in
PR China but also in Vietnam and South Korea. Infec-
tions occur when raw freshwater ﬁsh, harboring infec-
tive metacercariae, are consumed. Pathological
changes caused by C. sinensis infection are largely
conﬁned to the bile duct, liver, and gallbladder. Indi-
viduals with heavy infections often suffer from unspe-
ciﬁc symptoms, such as fever, fatigue, weakness,
nausea, or abdominal pain, but more severe conse-
quences, namely obstructive jaundice and biliary colic,
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might occur [2]. The most serious complication of C. sinensis
infection is cancer of the bile ducts, cholangiocarcinoma [3].
Praziquantel, administered at 3 doses of 25 mg/kg each at
5-hour intervals, is the drug of choice against clonorchiasis
[4]. This treatment schedule is highly efﬁcacious, with an egg
reduction rate (ERR) of 99% [5]. However, transient adverse
events, such as dizziness, sleepiness, headache, and diarrhea,
are commonly observed after praziquantel administration [4].
Effective alternative drugs with a good safety proﬁle are
not available.
The Chinese anthelmintic drug tribendimidine might be a
potential new drug candidate for treating infections with
C. sinensis. Tribendimidine was observed to be highly effective
in C. sinensis–infected rats [6] and in vitro [7]. In a random-
ized open-label trial in Lao People’s Democratic Republic (Lao
PDR), tribendimidine administered as a single oral dose of
200 mg (subjects <14 years of age) or 400 mg (subjects aged
≥14 years) to patients with parasitologically conﬁrmed Opis-
thorchis viverrini infections, a related liver ﬂuke, was found to
be as efﬁcacious as praziquantel (75 mg/kg given in 2 doses)
[8]. Clinical trials with tribendimidine have therefore been
suggested to determine the efﬁcacy and safety of this drug in
patients infected with C. sinensis [4, 9]. Tribendimidine is reg-
istered for human use for the treatment of infections with
soil-transmitted helminths in PR China. A consortium com-
posed of Chinese, Swiss, and US partners are currently
seeking regulatory approval for the use of tribendimidine
outside PR China [10], as studies in PR China have demon-
strated that the drug is safe and efﬁcacious against hookworm
and Ascaris lumbricoides infections [11, 12].
The aim of this trial was to study and compare the efﬁcacy
and safety of tribendimidine, given as a single-dose or 3-day
regimen, the latter already tested for the treatment of Trichuris
trichiura infection [13], with the standard treatment of prazi-
quantel in C. sinensis–infected individuals.
PATIENTS AND METHODS
Ethics Statement
The study was approved by the ethics committees in Basel,
Switzerland (EKBB; reference nos. 209/09 and 375/11), the
Liverpool School of Tropical Medicine (reference no.
12.02RS), and the National Institute of Parasitic Diseases,
Chinese Center for Disease Control and Prevention (reference
no. 2012–02).
Drugs
Tribendimidine (200 mg enteric-coated tablets) was purchased
from Shandong Xinhua Pharmaceutical Co, Ltd (Zibo, PR
China). Praziquantel (200 mg ﬁlm-coated tablets) was the
product of Nanjing Pharmaceutical Factory Co, Ltd (Nanjing,
PR China).
Study Area and Participants
The study was conducted from June to July 2012 in a C. sinen-
sis–endemic village (Hezhuang) located under the township of
Gantang, Binyang county, Guangxi Zhuang Autonomous
Region, PR China. Most villagers belong to the Zhuang ethnic
group and are farmers. Living standards are relatively low as
compared to the more developed regions of the country but
literacy rate is high, with all villagers having received at least
primary-school education.
Eligible individuals were adults of both sexes, aged ≥18
years. During the clinical examination by physicians, villagers
who had no major systemic, acute, or chronic illnesses, no
known or reported psychiatric or neurological disorders, or
hypersensitivity to tribendimidine or praziquantel, and were
not pregnant, were invited to join the study. Individuals were
excluded from trial participation if they had used any anthel-
mintic within the past month or were attending other clinical
trials during the same period. Only participants with written
informed consent, who provided 2 stool samples at baseline,
and were willing to provide another 2 stool samples 3 weeks
posttreatment were ﬁnally included in the study.
Study Flow, Sample Size, and Randomization
Our study was a randomized, open-label trial aiming to recruit
20–25 patients per treatment arm [14], similar to our earlier
study focusing on O. viverrini [8]. Villagers were invited to
provide a fresh morning stool sample in a container labeled
with a unique identiﬁer. Stool samples were transferred to the
laboratory of Binyang Center for Disease Control and Preven-
tion (CDC) and examined for the presence of C. sinensis eggs.
Patients with a parasitologically conﬁrmed C. sinensis infection
were asked to provide another stool sample over the next 5 days.
Written informed consent was obtained from C. sinensis–infect-
ed patients, and only consenting individuals were examined
clinically, which included a physical examination and the mea-
surement of height, weight, axillary temperature, blood pressure,
and pulse. Study participants were randomly allocated, using a
computer-generated randomization code prepared by an inde-
pendent statistician, into 3 treatment arms: (i) tribendimidine
400mg once, (ii) tribendimidine 400mg daily for 3 days, and
(iii) praziquantel 75mg/kg divided into 3 doses administered
within a day (Figure 1). All patients were treated on the same
day. Three and 24 hours after each dosing, each patient was
asked open-ended questions for the presence and severity of
adverse events. In a next step, the physicians asked for speciﬁc
adverse events. Adverse events were graded (ie, mild, moderate,
severe, and life threatening) [15], recorded in the case report forms
(CRFs), and remedial measures were taken if necessary. For
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each patient, the same physician performed the clinical exami-
nation and collected adverse events throughout all follow-ups.
Laboratory Procedure
From each stool sample, triplicate Kato-Katz thick smears,
using 41.7 mg templates, were prepared [16] and quantitatively
examined for C. sinensis eggs under a microscope by experi-
enced technicians, who were blinded to treatment allocation.
The number of A. lumbricoides, T. trichiura, hookworm, and
other helminth eggs were recorded separately. For quality
control, the 3 slides were independently read by different tech-
nicians, and the results compared. Slides were reread if incon-
sistencies were detected.
Outcome Measures and Statistics
Statistical analyses were performed with Stata version 10.0 (Sta-
taCorp, College Station, Texas). Available case analysis was em-
ployed and thus, only those patients who had primary outcome
data were used for analysis. Cure rate (CR) was deﬁned as the
proportion of C. sinensis egg–positive patients at baseline, who
became egg-negative 3 weeks after treatment. CRs represent-
ed as odds ratio (OR) between different treatment arms and
calculated from logistic regressions were also determined. Fecal
egg counts, as expressed as eggs per gram of stool (EPG), were
calculated by multiplying the sum of the egg counts from the 6
Kato-Katz thick smears by a factor of 4. Infection intensity of
C. sinensis was categorized as light (1–999 EPG), moderate
(1000–9999 EPG), and heavy (≥10 000 EPG) according to Yu
and colleagues [17]. ERRs for each treatment group were deter-
mined based on the geometric mean (GM) fecal egg counts
before and 3 weeks after treatment. The 95% conﬁdence inter-
vals (CIs) of ERR were calculated with bootstrap resampling.
The average dose (mg/kg) of tribendimidine was also deter-
mined and analyzed with a logistic regression to assess
whether the dose of treatment had an inﬂuence on the CR.
Other test statistics included χ2 test, Fisher exact test, and anal-
ysis of variance, as appropriate.
RESULTS
Adherence and Baseline Characteristics
From a recruitment pool of 96 individuals assessed for eligibil-
ity, 20 patients were excluded because they did not participate
Figure 1. Trial ﬂow diagram demonstrating patient compliance in a randomized open-label trial assessing the efﬁcacy and safety of tribendimidine
against C. sinensis in Guangxi, PR China, from June to July 2012.
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at the clinical examination (n = 18) or presented with chronic
or severe illnesses (n = 2). In total, 76 participants were ran-
domized to the 3 treatment arms. One patient discontinued
praziquantel treatment after 2 doses due to adverse events and
2 patients were lost to follow-up, giving an overall compliance
with treatment and follow-up of 96% (73/76).
Stool samples of the patient who discontinued praziquantel
treatment were collected at the follow-up, and hence this
patient was included in the available case analysis. Demo-
graphic and laboratory baseline characteristics of the 74 pa-
tients are summarized in Table 1. Fifty-seven participants
(77.0%) were male and 17 were female. Only 2 women were
randomized to the praziquantel treatment group. The mean
age in the 3 treatment arms ranged from 49.9 to 51.2 years.
The height ranged from 156 to 162 cm. Most of the patients
(n = 41) harbored a moderate C. sinensis infection (1000–9999
EPG). Fecal egg counts ranged from 124 to 31 244 EPG with a
GM of 2816 to 4051 EPG according to treatment arms.
Overall, 12, 2, and 1 patients were concurrently infected with
hookworm, T. trichiura, and A. lumbricoides, respectively.
Given the small number of soil-transmitted helminth infec-
tions, these were not considered further.
Efﬁcacy Against C. sinensis
Single-dose tribendimidine (400 mg) achieved a CR of 44%,
while CRs of 58% and 56% were obtained for 400 mg tribendi-
midine administered for 3 days and praziquantel, respectively
(Table 2). All patients harboring a light C. sinensis infection
Table 1. Demographic and Laboratory Baseline Characteristics of Clonorchis sinensis–Infected Patients in Guangxi, PR China, From
June to July 2012 (N = 74)
Treatment Group
Parameter
Tribendimidine
400mg Once
(n = 25)
Tribendimidine
400mg Once
Daily for 3 d
(n = 24)
Praziquantel
75mg/kg
Divided in 3
Doses (n = 25)
Males/females (no.) 19/6 15/9 23/2
Mean (SD) age, years 51.2 (8.8) 49.9 (10.1) 50.5 (10.0)
Mean (SD) weight, kg 61.9 (10.8) 58.3 (7.6) 60.4 (12.3)
Mean (SD) height, cm 157 (6) 156 (8) 162 (8)
C. sinensis infection intensity
Overall GM fecal egg counts, EPG 3387 2816 4051
Fecal egg counts (range), EPG (124–29 624) (184–18 772) (212–31 244)
No. of light infections (1–999 EPG) 5 4 4
No. of moderate infections (1000–9999 EPG) 11 17 13
No. of heavy infections (≥10 000 EPG) 9 3 8
Abbreviations: EPG, eggs per gram of stool; GM, geometric mean; SD, standard deviation.
Table 2. Effect of Tribendimidine Single and Triple Dosages and Praziquantel in Patients Infected With Clonorchis sinensis in
Guangxi, PR China, From June to July 2012 (N = 74)
Treatment Group
Parameter
Tribendimidine 400mg
Once (n = 25)
Tribendimidine 400mg
Once Daily for 3 d
(n = 24)
Praziquantel 75mg/kg
Divided in 3 Doses
(n = 25)
No. of patients cured (%) 11 (44) 14 (58) 14 (56)
No. of patients cured of light infection (%) 5 (100) 4 (100) 4 (100)
No. of patients cured of moderate infection (%) 6 (54) 10 (59) 7 (54)
No. of patients cured of heavy infection (%) 0 0 3 (38)
C. sinensis infection intensity
Overall GM fecal egg counts, EPG 80.0 35.1 50.0
Fecal egg counts (range), EPG (0–3636) (0–1296) (0–1876)
Egg reduction rate (%) (95% CI) 97.6 (93.0–98.6) 98.8 (96.9–99.6) 98.8 (97.0–99.6)
Abbreviations: CI, confidence interval; EPG, eggs per gram of stool; GM, geometric mean.
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(1–999 EPG) were cured regardless of the treatment adminis-
tered. In all 3 treatment arms, CRs of 54%–59% were observed
against moderate (1000–9999 EPG) infections. Praziquantel
was able to cure 3 of 8 patients with a heavy C. sinensis infec-
tion (≥10 000 EPG), while tribendimidine failed to cure such
heavy infections regardless of dose. High ERRs (97.6%–98.8%)
were observed for all treatments. Tribendimidine administered
once daily for 3 days had 10% higher odds of curing a C. si-
nensis infection than praziquantel. On the other hand, single-
dose tribendimidine had 38% and 44% lower odds of curing
C. sinensis infection than praziquantel and the 3-day tribendi-
midine regimen, respectively. However, no signiﬁcant differ-
ences were observed for the treatment outcomes in the
praziquantel treatment arm vs tribendimidine single-dose or
given for 3 days, and between both tribendimidine regimens.
The actual dose of tribendimidine administered ranged
from 4.9 to 9.1 mg/kg for the single-dose and 16.9–29.6 mg/kg
for the 3-day regimen. No signiﬁcant association between CRs
and dose was observed.
Adverse Events
No life-threatening adverse events were observed following
treatment. One patient treated with praziquantel experienced
severe vomiting and discontinued treatment (the patient did
not take the third dose). Most adverse event episodes were
mild (n = 121), with 9 moderate or heavy adverse events either
at 3 hours (n = 2) or 24 hours (n = 7). Table 3 summarizes the
number of patients experiencing adverse events, stratiﬁed by
treatment arm at the different examination time points, while
Supplementary Table 1 presents the number of adverse events
reported at different time points after treatment.
Single-dose tribendimidine was the best-tolerated treatment
scheme. Eleven patients treated with a single dose of tribendi-
midine complained of adverse events, with dizziness/faintness
the predominant adverse event reported by 5 patients.
However, this symptom was already stated by 3 patients before
treatment. Adverse events were reported among 16 patients
who were given tribendimidine daily for 3 days, dizziness/
faintness being the most commonly reported symptom.
Patients treated with praziquantel experienced signiﬁcantly
more adverse events than patients given tribendimidine
(P < .05). Dizziness/faintness was signiﬁcantly more often re-
ported by patients treated with praziquantel than in patients
treated with tribendimidine (P < .05). Praziquantel-treated pa-
tients also experienced abdominal pain, vomiting, and nausea.
Adverse events labeled as “others” that were commonly re-
ported by praziquantel-treated and tribendimidine-treated pa-
tients were bloatedness and dry mouth, respectively.
DISCUSSION
Clonorchiasis is a public health problem in PR China, yet only
a single treatment—praziquantel—is currently available [18].
Table 3. Number of Patients With Adverse Events Among the 3 Treatment Arms, as Assessed at Different Time Points, in a Randomized
Open-Label Trial Assessing the Efﬁcacy and Safety of Tribendimidine Against Clonorchis sinensis in Guangxi, PR China, From June to
July 2012a
Treatment Group
Time Point
Tribendimidine
400mg Once
Tribendimidine
400mg Once
Daily for 3 d
Praziquantel 75mg/kg
Divided in 3 Doses
Related symptoms before treatment 3 (12) 1 (4) 4 (16)
No. of patients with adverse events (%)
3 hours after first treatment 5 (20)b 9 (38) 12 (48)
24 hours after first treatment 7 (28) 10 (42) NA
3 hours after second treatment NA 2 (8)c 16 (64)
24 hours after second treatment NA 4 (16) NA
3 hours after third treatment NA 3 (12.5) NAd
24 hours after third treatment NA 1 (4)c 17 (71)
Overall number of patients experiencing
adverse events at any time point
11 (44)b 16 (67)b 23 (92)
Abbreviation: NA, not applicable.
a P values were calculated using χ2 or Fisher exact test, as appropriate.
b Significantly different from praziquantel group (P < .05).
c Significantly different from praziquantel group (P < .001).
d The third treatment of praziquantel was administered in the evening and it was logistically impossible for the patients to report back 3 hours after treatment.
Thus, adverse events were only recorded 24 hours after treatment.
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Repurposing existing medicines cuts drug development costs
and might provide alternative treatments in a timely manner
[19, 20]. We studied tribendimidine, a Chinese broad-
spectrum anthelmintic drug marketed for the treatment of
soil-transmitted helminthiases, against infections with the
liver ﬂuke C. sinensis in a randomized open-label trial.
We found that single-dose tribendimidine (400 mg)
achieved a high ERR and moderate CR in patients infected
with C. sinensis, an efﬁcacy proﬁle comparable to standard
triple-dose praziquantel. Moreover, tribendimidine was better
tolerated than triple-dose praziquantel. Indeed, and in line
with ﬁndings from previous studies [21, 22], praziquantel-
treated patients commonly reported dizziness, abdominal
pain, nausea, and vomiting. It is interesting to note that dizzi-
ness has also been reported previously in praziquantel-treated
patients infected with O. viverrini [8] and Hymenolepis nana
[23]. To our knowledge, it is not known why praziquantel
causes dizziness. More investigation into this issue is warrant-
ed, as praziquantel is routinely used in preventive chemother-
apy, and dizziness as a common adverse event is not desirable.
Our results conﬁrm recent results obtained with single-dose
tribendimidine in patients infected with O. viverrini in Lao
PDR. Indeed, in that proof-of-concept study, 19 of 27 O. viver-
rini–infected-patients were cured (70%) and an ERR of over
99% was achieved. In line with our ﬁndings, tribendimidine
was better tolerated than praziquantel [8].
Though our study was not designed as an equivalence trial,
our ﬁndings hint that single-dose tribendimidine is equally ef-
ﬁcacious as 3 doses of the drug. Note that in preventive che-
motherapy programs, which aim to prevent morbidity due to
helminthiases using the available armamentarium of anthel-
mintics, drugs are administered as single doses to entire at
risk-populations without prior diagnosis, often in remote rural
areas where access to public services is a formidable challenge
[24]. A clonorchicidal drug, which is effective as a single dose,
would therefore greatly facilitate preventive chemotherapy
programs.
In terms of CR, all 3 treatment regimens had an excellent
efﬁcacy against light infections and a reasonable efﬁcacy
against moderate infections, but a poor efﬁcacy against heavy
C. sinensis infections. The differing susceptibility to prazi-
quantel depending on infection intensity of trematode infec-
tions is well known [22, 25], and therefore different doses and
treatment schedules have been proposed [22]. For example,
praziquantel given at 3 × 25 mg/kg was found to be superior
to a single dose of 40 mg/kg, in particular for C. sinensis infec-
tion of heavy intensities [22]. It has been suggested that
genetic polymorphism might be a reason for the low efﬁcacy
of praziquantel against heavy C. sinensis infection. For
example, patients with a particular single-nucleotide polymor-
phism of their cytochrome P450 gene revealed lower CRs than
patients without [26]. In addition, genetic diversity of C. si-
nensis could also play a factor in the success of praziquantel
treatment, with strains in Southeast Asia showing lower sus-
ceptibility to the drug than strains from East Asia [27, 28].
Because soil-transmitted helminthiases and clonorchiasis
often overlap geographically [29], praziquantel and albenda-
zole have been coadministered in areas where trematode (eg,
C. sinensis and O. viverrini) and nematode infections (eg, soil-
transmitted helminths) coexist [30]. Our ﬁndings point to an
additional beneﬁt of tribendimidine; because of the broad
spectrum of activity of this drug, concurrent infections with
soil-transmitted helminths and liver ﬂukes could be targeted
in one go. In the present setting, only few C. sinensis–infected
patients were coinfected, and hence the efﬁcacy and safety of
tribendimidine in patients infected with both soil-transmitted
helminths and liver ﬂukes remains to be investigated.
In conclusion, our results suggest that single-dose tribendi-
midine is comparable to triple-dose praziquantel, both in
terms of efﬁcacy and safety, in the treatment of C. sinensis in-
fections. Larger clinical trials, which have been initiated with
O. viverrini–infected patients in Lao PDR, should also be
planned in C. sinensis–infected patients.
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